NCT05256225 2026-03-18
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Institut Curie
American Society of Clinical Oncology
Cancer Research UK
Cancer Research UK
Rigshospitalet, Denmark
Isala